# Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

> **NCT00513877** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 33 (actual)

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** bortezomib
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00513877
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513877, "Bortezomib in Treating Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00513877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*